The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
QUINOLINIC ACID AND KYNURENINE PATHWAY METABOLISM IN INFLAMMATORY AND NON-INFLAMMATORY NEUROLOGICAL DISEASE
Abstract
Neurological dysfunction, seizures and brain atrophy occur in a broad spectrum of acute and chronic neurological diseases. In certain instances, over-stimulation of N-methyl-D-aspartate receptors has been implicated. Quinolinic acid (QUIN) is an endogenous N-methyl-D-aspartate receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction. Conversely, the related metabolite, kynurenic acid, is an antagonist of N-methyl-D-aspartate receptors and could modulate the neurotoxic effects of QUIN as well as disrupt excitatory amino acid neurotransmission. In the present study, markedly increased concentrations of QUIN were found in both lumbar cerebrospinal fluid (CSF) and post-mortem brain tissue of patients with inflammatory diseases (bacterial, viral, fungal and parasitic infections, meningitis, autoimmune diseases and septicaemia) independent of breakdown of the blood-brain barrier. The concentrations of kynurenic acid were also increased, but generally to a lesser degree than the increases in QUIN. In contrast, no increases in CSF QUIN were found in chronic neurodegenerative disorders, depression or myoclonic seizure disorders, while CSF kynurenic acid concentrations were significantly lower in Huntington's disease and Alzheimer's disease. In inflammatory disease patients, proportional increases in CSF L-kynurenine and reduced L-tryptophan accompanied the increases in CSF QUIN and kynurenic acid. These responses are consistent with induction of indoleamine-2,3-dioxygenase, the first enzyme of the kynurenine pathway which converts L-tryptophan to kynurenic acid and QUIN. Indeed, increases in both indoleamine-2,3-dioxygenase activity and QUIN concentrations were observed in the cerebral cortex of macaques infected with retrovirus, particularly those with local inflammatory lesions. Correlations between CSF QUIN, kynurenic acid and L-kynurenine with markers of immune stimulation (neopterin, white blood cell counts and IgG levels) indicate a relationship between accelerated kynurenine pathway metabolism and the degree of intracerebral immune stimulation. We conclude that inflammatory diseases are associated with accumulation of QUIN, kynurenic acid and L-kynurenine within the central nervous system, but that the available data do not support a role for QUIN in the aetiology of Huntington's disease or Alzheimer's disease. In conjunction with our previous reports that CSF QUIN concentrations are correlated to objective measures of neuropsychological deficits in HIV-1-infected patients, we hypothesize that QUIN and kynurenic acid are mediators of neuronal dysfunction and nerve cell death in inflammatory diseases. Therefore, strategies to attenuate the neurological effects of kynurenine pathway metabolites or attenuate the rate of their synthesis offer new approaches to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monaghan, D. T., Bridges, R. J., & Cotman, C. W. (1989) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.29.040189.002053 · Cited by 2,194
Excitatory amino acid neurotoxicity and neurodegenerative disease
Meldrum, B., & Garthwaite, J. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90184-a · Cited by 1,771
Chronic Fatigue Syndrome: A Working Case Definition
HOLMES, G. P., KAPLAN, J. E., GANTZ, N. M., KOMAROFF, A. L., SCHONBERGER, L. B., STRAUS, S. E., JONES, J. F., DUBOIS, R. E., CUNNINGHAM-RUNDLES, C., PAHWA, S., et al. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-387 · Cited by 1,718
Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid
Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986) · Nature · doi:10.1038/321168a0 · Cited by 1,286
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism
Taylor, M. W., & Feng, G. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.11.1907934 · Cited by 1,060
Tibbling, G., Link, H., & Ohman, S. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517709091496 · Cited by 966
Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism
Fukui, S., Schwarcz, R., Rapoport, S. I., Takada, Y., & Smith, Q. R. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb03460.x · Cited by 761
Secretion of Neurotoxins by Mononuclear Phagocytes Infected with HIV-1
Giulian, D., Vaca, K., & Noonan, C. A. (1990) · Science · doi:10.1126/science.2148832 · Cited by 620
Heyes, M. P., Brew, B. J., Martin, A., Price, R. W., Salazar, A. M., Sidtis, J. J., Yergey, J. A., Mouradian, M. M., Sadler, A. E., Keilp, J., et al. (1991) · Annals of Neurology · doi:10.1002/ana.410290215 · Cited by 571
Self-citation
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“Kynurenine 3-monooxygenase (KMO) enzyme, which is predominantly expressed in microglia, catalyzes the conversion of L-kynurenine to 3-hydroxykynurenine (3-HK) in the kynurenine pathway.(450) R6/2 HD mice treated with the KMO inhibitor JM6 showed a decrease in synaptic degeneration and a longer lifespan by reducing mic…”
BackgroundKynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Tryptophan metabolism in health and disease
Xue, C., Li, G., Zheng, Q., Gu, X., Shi, Q., Su, Y., Chu, Q., Yuan, X., Bao, Z., Lu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.004 · Cited by 961
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways
Houtkooper, R. H., Cantó, C., Wanders, R. J., & Auwerx, J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0026 · Cited by 899
Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
Endogenous kynurenines as targets for drug discovery and development
Stone, T. W., & Darlington, L. G. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd870 · Cited by 768
Inflammation-associated depression: From serotonin to kynurenine
Dantzer, R., O’Connor, J. C., Lawson, M. A., & Kelley, K. W. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.09.012 · Cited by 726
The Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723
Regulation and Function of T-Cell-Mediated Immunity during Toxoplasma gondii Infection
Denkers, E. Y., & Gazzinelli, R. T. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.4.569 · Cited by 701
Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35
Wang, J., Simonavicius, N., Wu, X., Swaminath, G., Reagan, J., Tian, H., & Ling, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603503200 · Cited by 687
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Self-citationKynurenine Pathway Metabolites in Humans: Disease and Healthy States
Chen, Y., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 628
Major Depression and Activation of The Inflammatory Response System
Maes, M. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_2 · Cited by 617
Large-Scale Multi-omic Analysis of COVID-19 Severity
Overmyer, K. A., Shishkova, E., Miller, I. J., Balnis, J., Bernstein, M. N., Peters-Clarke, T. M., Meyer, J. G., Quan, Q., Muehlbauer, L. K., Trujillo, E. A., et al. (2021) · Cell Systems · doi:10.1016/j.cels.2020.10.003 · Cited by 606
Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression
Wang, H., He, Y., Sun, Z., Ren, S., Liu, M., Wang, G., & Yang, J. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02492-0 · Cited by 571
Monitoring tryptophan metabolism in chronic immune activation
Schröcksnadel, K., Wirleitner, B., Winkler, C., & Fuchs, D. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.013 · Cited by 551
Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection
Guillemin, G. J., Kerr, S. J., Smythe, G. A., Smith, D. G., Kapoor, V., Armati, P. J., Croitoru, J., & Brew, B. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00498.x · Cited by 538
Minagar, A., Shapshak, P., Fujimura, R., Ownby, R., Heyes, M., & Eisdorfer, C. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00207-1 · Cited by 537
Self-citationMacrophage de novo NAD+ synthesis specifies immune function in aging and inflammation
Minhas, P. S., Liu, L., Moon, P. K., Joshi, A. U., Dove, C., Mhatre, S., Contrepois, K., Wang, Q., Lee, B. A., Coronado, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0255-3 · Cited by 501
Kynurenine pathway in major depression: Evidence of impaired neuroprotection
Myint, A.-M., Kim, Y. K., Verkerk, R., Scharpé, S., Steinbusch, H., & Leonard, B. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.07.013 · Cited by 527
Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration
Zwilling, D., Huang, S.-Y., Sathyasaikumar, K. V., Notarangelo, F. M., Guidetti, P., Wu, H.-Q., Lee, J., Truong, J., Andrews-Zwilling, Y., Hsieh, E. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.05.020 · Cited by 515
Sas, K., Robotka, H., Toldi, J., & Vécsei, L. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.033 · Cited by 463
Human macrophages convert l-tryptophan into the neurotoxin quinolinic acid
Heyes, M. P., Saito, K., & Markey, S. P. (1992) · Biochemical Journal · doi:10.1042/bj2830633 · Cited by 447
Self-citationParvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
BEASLEY, C., & REYNOLDS, G. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00122-3 · Cited by 426
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Serotonergic vulnerability and depression: assumptions, experimental evidence and implications
Jans, L. A. W., Riedel, W. J., Markus, C. R., & Blokland, A. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001920 · Cited by 374
Connecting inflammation with glutamate agonism in suicidality
Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345
Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites
Moroni, F. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00196-x · Cited by 346
Puntel, R. L., Nogueira, C. W., & Rocha, J. B. T. (2005) · Neurochemical Research · doi:10.1007/s11064-004-2445-7 · Cited by 346
Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus
Guillemin, G. J., Brew, B. J., Noonan, C. E., Takikawa, O., & Cullen, K. M. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00655.x · Cited by 330
The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans
Wichers, M., & Maes, M. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003103 · Cited by 329
Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression
Kim, H., Chen, L., Lim, G., Sung, B., Wang, S., McCabe, M. F., Rusanescu, G., Yang, L., Tian, Y., & Mao, J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61884 · Cited by 324
Cytokines: abnormalities in major depression and implications for pharmacological treatment
O'Brien, S. M., Scott, L. V., & Dinan, T. G. (2004) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.609 · Cited by 320
Oxidative Damage in Huntington's Disease Pathogenesis
Browne, S. E., & Beal, M. F. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.2061 · Cited by 310
Tryptophan metabolism and oxidative stress in patients with Huntington's disease
Stoy, N., Mackay, G. M., Forrest, C. M., Christofides, J., Egerton, M., Stone, T. W., & Darlington, L. G. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03070.x · Cited by 310
Kynurenines in the CNS: from endogenous obscurity to therapeutic importance
Stone, T. W. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00032-0 · Cited by 306
The kynurenine pathway and neurodegenerative disease
Maddison, D. C., & Giorgini, F. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.03.002 · Cited by 309
Bay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304
Cerebrospinal Fluid and Serum Markers of Inflammation in Autism
Zimmerman, A. W., Jyonouchi, H., Comi, A. M., Connors, S. L., Milstien, S., Varsou, A., & Heyes, M. P. (2005) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.03.014 · Cited by 300
Self-citationTryptophan in health and disease
(2020) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2019.08.005 · Cited by 294
Enzymology of NAD+ homeostasis in man
Magni, G., Amici, A., Emanuelli, M., Orsomando, G., Raffaelli, N., & Ruggieri, S. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3161-1 · Cited by 288
Tryptophan degradation and immune activation in Alzheimer's disease
Widner, B., Leblhuber, F., Walli, J., Tilz, G. P., Demel, U., & Fuchs, D. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050029 · Cited by 286
Wichers, M. C., & Maes, M. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0402 · Cited by 285
Kynurenine and its metabolites in Alzheimer's disease patients
Gulaj, E., Pawlak, K., Bien, B., & Pawlak, D. (2010) · Advances in Medical Sciences · doi:10.2478/v10039-010-0023-6 · Cited by 285
Reconstructing eukaryotic NAD metabolism
Rongvaux, A., Andris, F., Van Gool, F., & Leo, O. (2003) · BioEssays · doi:10.1002/bies.10297 · Cited by 280
Drexhage, R. C., Knijff, E. M., Padmos, R. C., Heul-Nieuwenhuijzen, L. V. D., Beumer, W., Versnel, M. A., & Drexhage, H. A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.144 · Cited by 263
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease
GUIDETTI, P., LUTHICARTER, R., AUGOOD, S., & SCHWARCZ, R. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.006 · Cited by 260
The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons
Rahman, A., Ting, K., Cullen, K. M., Braidy, N., Brew, B. J., & Guillemin, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006344 · Cited by 257
Saito, K., Suyama, K., Nishida, K., Sei, Y., & Basile, A. S. (1996) · Neuroscience Letters · doi:10.1016/s0304-3940(96)12460-5 · Cited by 257
Self-citationNetwork beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis
Myint, A.-M., & Kim, Y.-K. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.08.008 · Cited by 230
Bull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228
Fujigaki, H., Saito, K., Fujigaki, S., Takemura, M., Sudo, K., Ishiguro, H., & Seishima, M. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvj072 · Cited by 222
Self-citationBrundin, L., Sellgren, C. M., Lim, C. K., Grit, J., Pålsson, E., Landén, M., Samuelsson, M., Lundgren, K., Brundin, P., Fuchs, D., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.133 · Cited by 195
Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients
Huengsberg, M., Winer, J. B., Gompels, M., Round, R., Ross, J., & Shahmanesh, M. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.4.858 · Cited by 172
Microglial activation in the pathogenesis of Huntington's disease
Yang, H.-M., Yang, S., Huang, S.-S., Tang, B.-S., & Guo, J.-F. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00193 · Cited by 151
Quinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α
PEMBERTON, L. A., KERR, S. J., SMYTHE, G., & BREW, B. J. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.589 · Cited by 149
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A., & Urbanska, E. M. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13768 · Cited by 142
Depression as a Risk Factor for Cancer: From Pathophysiological Advances to Treatment Implications
Currier, M. B., & Nemeroff, C. B. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061212-171507 · Cited by 126
Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research
Jung, E. S., Choi, H., & Mook-Jung, I. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00825-0 · Cited by 124
The role of the kynurenine pathway in suicidality in adolescent major depressive disorder
Bradley, K. A. L., Case, J. A. C., Khan, O., Ricart, T., Hanna, A., Alonso, C. M., & Gabbay, V. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.03.031 · Cited by 115
Obuchowicz, E., Kowalski, J., Labuzek, K., Krysiak, R., Pendzich, J., & Herman, Z. S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500547x · Cited by 115
Acute tryptophan depletion in humans: a review of theoretical, practical and ethical aspects
Young, S. N. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120209 · Cited by 110
Diverse effects of gut-derived serotonin in intestinal inflammation
Shajib, M. S., Baranov, A., & Khan, W. I. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00414 · Cited by 109
Riis, J. L., Out, D., Dorn, L. D., Beal, S. J., Denson, L. A., Pabst, S., Jaedicke, K., & Granger, D. A. (2014) · Developmental Psychobiology · doi:10.1002/dev.21149 · Cited by 108
Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis
Guillemin, G. J., Meininger, V., & Brew, B. J. (2005) · Neurodegenerative Diseases · doi:10.1159/000089622 · Cited by 105
Watkins, C. C., Sawa, A., & Pomper, M. G. (2014) · Translational Psychiatry · doi:10.1038/tp.2013.119 · Cited by 100
Structural and functional characterization of the gut microbiota in elderly women with migraine
Chen, J., Wang, Q., Wang, A., & Lin, Z. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00470 · Cited by 89
Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease
Meßmer, K., & Reynolds, G. P. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00967-1 · Cited by 89
Smith, A. K., Simon, J. S., Gustafson, E. L., Noviello, S., Cubells, J. F., Epstein, M. P., Devlin, D. J., Qiu, P., Albrecht, J. K., Brass, C. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.67 · Cited by 84
Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients
González-Sánchez, M., Jiménez, J., Narváez, A., Antequera, D., Llamas-Velasco, S., Martín, A. H.-S., Molina Arjona, J. A., López de Munain, A., Lleó Bisa, A., Marco, M.-P., et al. (2020) · Biomolecules · doi:10.3390/biom10040571 · Cited by 84
“Our results agree with those previously reported by Jacobs and colleagues, as they did not find any significant correlations between Aβ42 levels in CSF and KP metabolites in samples from AD patients [34].”
BackgroundResultSelf-citationPathobiological targets of depression
Chopra, K., Kumar, B., & Kuhad, A. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.553603 · Cited by 76
Nitric oxide synthase inhibition prevents acute quinolinate-induced striatal neurotoxicity
Pérez-Severiano, F., Escalante, B., & Ríos, C. (1998) · Neurochemical Research · doi:10.1023/a:1020700401678 · Cited by 68
Yamada, A., Akimoto, H., Kagawa, S., Guillemin, G. J., & Takikawa, O. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06175.x · Cited by 58
Barton, S., Navarro, S. L., Buas, M. F., Schwarz, Y., Gu, H., Djukovic, D., Raftery, D., Kratz, M., Neuhouser, M. L., & Lampe, J. W. (2015) · Food & Function · doi:10.1039/c5fo00287g · Cited by 55
Salemi, J., Obregon, D. F., Cobb, A., Reed, S., Sadic, E., Jin, J., Fernandez, F., Tan, J., & Giunta, B. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-3 · Cited by 28
Du, X., Zou, S., Yue, Y., Fang, X., Wu, Y., Wu, S., Wang, H., Li, Z., Zhao, X., Yin, M., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04176-8 · Cited by 23
Kynurenic Acid Metabolism in Various Types of Brain Pathology in HIV-1 Infected Patients
Baran, H., Hainfellner, J. A., & Kepplinger, B. (2012) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s10627 · Cited by 19
Metadata
- Authors
- HEYES, M. P., SAITO, K., CROWLEY, J. S., DAVIS, L. E., DEMITRACK, M. A., DER, M., DILLING, L. A., ELIA, J., KRUESI, M. J. P., LACKNER, A., LARSEN, S. A., LEE, K., LEONARD, H. L., MARKEY, S. P., MARTIN, A., MILSTEIN, S., MOURADIAN, M. M., PRANZATELLI, M. R., QUEARRY, B. J., SALAZAR, A., SMITH, M., STRAUSS, S. E., SUNDERLAND, T., SWEDO, S. W., & TOURTELLOTTE, W. W.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 1992
- Volume
- 115
- Issue
- 5
- Pages
- 1249-1273
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2010145371
- Cited by
- 680
- References
- 46
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.